ViroCell Biologics has secured approval from the U.K.’s healthcare regulator to begin manufacturing and exporting the viral vector products it makes at a leading children’s hospital.

The London- and New York-based CDMO was given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA) to produce viral vectors from a manufacturing facility at the Zayed Centre for Research at the Great Ormond Street Hospital in London, the company said in a Nov. 1 press release.

Click the link in the title to read more

News from Disruptive capital GP Limited